Sue Fletcher

USPTO Granted Patents = 41 (Patent Applications = 28)

CIPO Patents = 1 (Patent Applications = 4)

EPO Patents = 6 (Patent Applications = 19)

Average Co-Inventor Count = 3.2

ph-index = 29

Forward Citations = 2,194(Granted Patents)

Company Filing History:

36 out of 106

The University of Western Australia

Sarepta Therapeutics, Inc.

patents

4. 2 out of 893

Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.

patents

where one patent can have more than one assignee

Years Active: 2010-2022

Loading Chart...

Areas of Expertise:

Antisense Oligonucleotides

Exon Skipping

NEAT1 Associated Disease

CFTR Function Restoration

Splicing Modulation

Multiple Sclerosis Treatment

Pathology Treatment

Molecular Therapeutics

41 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11459563 - Treatment for NEAT1 associated disease (2022-10-04),

2. 11447776 - Antisense molecules and methods for treating pathologies (2022-09-20),

3. RE48960 - Antisense oligonucleotides for inducing exon skipping and methods of use thereof (2022-03-07),

4. 11236338 - Antisense-induced exon2 inclusion in acid alpha-glucosidase (2022-02-01),

5. 10995337 - Antisense oligonucleotides for inducing exon skipping and methods of use thereof (2021-05-04),

6. 10968450 - Antisense oligonucleotides for inducing exon skipping and methods of use thereof (2021-04-06),

7. 10781451 - Antisense oligonucleotides for inducing exon skipping and methods of use thereof (2020-09-22),

8. 10781450 - Antisense molecules and methods for treating pathologies (2020-09-22),

9. 10731156 - Restoration of the CFTR function by splicing modulation (2020-08-04),

10. RE47769 - Antisense oligonucleotides for inducing exon skipping and methods of use thereof (2019-12-16),

11. RE47751 - Antisense oligonucleotides for inducing exon skipping and methods of use thereof (2019-12-02),

12. RE47691 - Antisense oligonucleotides for inducing exon skipping and methods of use thereof (2019-11-04),

13. 10428328 - Restoration of the CFTR function by splicing modulation (2019-10-01),

14. 10421966 - Antisense oligonucleotides for inducing exon skipping and methods of use thereof (2019-09-24),

15. 10376536 - Multiple sclerosis treatment (2019-08-13),

Title: Celebrating the Innovations of Sue Fletcher

Introduction

Sue Fletcher is a prominent inventor based in Bayswater, Australia, known for her groundbreaking contributions to the field of biomedical research. With an impressive portfolio of 41 patents, her work has significantly advanced the understanding and treatment of various diseases, particularly those related to RNA processing.

Latest Patents

Fletcher's latest patents demonstrate her innovative approach to addressing complex medical challenges. One notable patent is focused on a treatment for NEAT1 associated disease, which centers on an isolated or purified antisense oligomer designed to modify RNA cleavage and processing in the NEAT1 gene transcript. Another significant patent involves antisense molecules and methods for treating pathologies. This invention presents an antisense molecule capable of binding to a selected target site to induce exon skipping in the dystrophin gene, highlighting her commitment to developing therapies for genetic conditions.

Career Highlights

Throughout her career, Sue Fletcher has made remarkable strides in the academic realm. She has been affiliated with reputable institutions such as The University of Western Australia and Murdoch University, where she has contributed her expertise to various research projects and initiatives. Her extensive background in biomedical research underscores her dedication to innovation and the pursuit of new medical solutions.

Collaborations

Fletcher has collaborated with notable figures in her field, including Stephen Donald Wilton and Graham McClorey. These collaborations have facilitated the sharing of ideas and expertise, further advancing the development of her innovative treatments and research initiatives.

Conclusion

Sue Fletcher's work exemplifies the spirit of innovation in biomedical research. With her substantial number of patents and collaborative efforts, she continues to impact the scientific community positively. Her dedication to addressing complex health issues through her inventions ensures that she remains an influential figure in the field.

This text is generated by artificial intelligence and may not be accurate.